A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer

The optimal management of patients with oligorecurrent prostate cancer (PCa) is unknown. There is growing interest in metastasis-directed therapy (MDT) for this population. The objective was to assess cost-utility from a Belgian healthcare payer’s perspective of MDT and delayed androgen deprivation...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: De Bleser, Elise, Willems, Ruben, Decaestecker, Karel, Annemans, Lieven, De Bruycker, Aurélie, Fonteyne, Valérie, Lumen, Nicolaas, Ameye, Filip, Billiet, Ignace, Joniau, Steven, De Meerleer, Gert, Ost, Piet, Bultijnck, Renée
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7016808/
https://ncbi.nlm.nih.gov/pubmed/31947974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12010132
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak